Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

4498 - Patient Preferences for breast cancer treatments: A Discrete Choice Experiment from four European countries


29 Sep 2019


Poster Display session 2


Tumour Site

Breast Cancer


Thomais Konstantopoulou


Annals of Oncology (2019) 30 (suppl_5): v104-v142. 10.1093/annonc/mdz242


T. Konstantopoulou1, E. Stamuli2, D. Ross3, R. Pacheco4

Author affiliations

  • 1 Market Access, Novartis Farma Italy, 21040 - Origgio/IT
  • 2 Health Economics, Pharmecons Easy Access, YO31 0AA - York/GB
  • 3 Social Sciences, Trinity University, Chapelizod - Dublin/IE
  • 4 Medical Department, Novartis Farma - Produtos Farmaceuticos S.A., 2740-255 - Porto Salvo/PT


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4498


Patients’ involvement in the health technology assessment (HTA) decision-making process is important for transparency, legitimacy and fairness. The study objectives were to understand breast cancer patients’ perspectives when choosing their treatment, highlight treatment characteristics valued as most important by patients and gain information on patients’ trade-offs between available treatments.


A discrete choice experiment survey of breast cancer patients was conducted in Spain, Poland, France and Ireland. The survey design included: literature review, qualitative research, cognitive debriefing, data collection and analysis. A panel of experts from participating countries (physicians, patient group representatives, ex-payers) selected the survey treatment attributes: progression-free survival (PFS), febrile neutropenia (FN), pain, functional well-being (FWB) and out-of-pocket payment (OPP). Patients selected (or opted-out) between two unlabelled hypothetical treatments containing the previously mentioned five attributes. Panels of breast cancer patients were recruited as respondents and the questionnaire was deployed through a website platform. A D-efficient experimental design with 16 choice-sets was constructed and a conditional logistic model was used to estimate patients’ preferences. Marginal rates of substitution (MRS) was used to estimate out-of-pocket payments.


In total, 317 breast cancer patients completed the survey. FWB and pain were the most important attributes chosen by patients. Respondents were willing to pay €17,288 out-of-pocket to move from severe to no impairment in FWB, followed by moderate impairment (€15,297) and from severe pain to no pain state (€15,138). Patients would pay €574 annually for one additional PFS month. Preferences differed by age for FN and FWB; highly educated patients have stronger preference for PFS compared to non-highly educated.


Breast cancer treatments that improve pain, FWB and PFS are considered preferred treatments from patients’ perspective.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Novartis Oncology Region Europe.


Novartis Oncology Region Europe.


T. Konstantopoulou: Full / Part-time employment: Novartis Oncology. E. Stamuli: Research grant / Funding (institution): Novartis Oncology Region Europe. D. Ross: Advisory / Consultancy: Novartis Oncology Region Europe. R. Pacheco: Full / Part-time employment: Novartis Oncology Region Europe.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.